Tyra Biosciences Announces Promising Preclinical Results for TYRA-300 in FGFR3-related Skeletal Dysplasia at ENDO 2025

Reuters
09 Jul
<a href="https://laohu8.com/S/TYRA">Tyra Biosciences</a> Announces Promising Preclinical Results for TYRA-300 in FGFR3-related Skeletal Dysplasia at ENDO 2025

Tyra Biosciences Inc., a clinical-stage biotechnology company, has announced the upcoming presentation of preclinical results for their investigational drug, TYRA-300, at The Endocrine Society's Annual Meeting (ENDO 2025) in San Francisco, CA. The late-breaking poster presentation, titled "TYRA-300 Promotes Bone Growth In Two Mouse Models Of FGFR3-related Skeletal Dysplasia," will be delivered by Dr. Jacqueline H. Starrett on July 13, 2025. This study focuses on the potential of TYRA-300 to address bone growth challenges associated with FGFR3-related skeletal dysplasia. The session will be part of the BONE AND MINERAL METABOLISM track, focusing on rare bone and genetic disorders. Further details and access to the poster will be available on Tyra Biosciences' website following the conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tyra Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA25235) on July 08, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10